Genetic variation in PCAF, a key mediator in epigenetics, is associated with reduced vascular morbidity and mortality: Evidence for a new concept from three independent prospective studies

Heart

Volumn 97, Issue 2, 2011, Pages 143-150

  Pons, Douwe ^a,b   Trompet, Stella ^a   De Craen, Anton J M ^a   Thijssen, Peter E ^a   Quax, Paul H A ^a   De Vries, Margreet R ^a   Wierda, Rutger J ^a   Van Den Elsen, Peter J ^a,c   Monraats, Pascalle S ^a   Ewing, Mark M ^a   Heijmans, Bastiaan T ^a   Slagboom, P Eline ^a   Zwinderman, Aeilko H ^d   Doevendans, Pieter A F M ^b,e   Tio, René A ^b,f   De Winter, Robbert J ^d   De Maat, Moniek P M ^g   Iakoubova, Olga A ^h   Sattar, Naveed ⁱ   Shepherd, Jim ^j   Westendorp, Rudi G J ^a   Jukema, J Wouter ^a,b,k   more..

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h CELERA   (United States)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

^k Durrer Center for Cardiogenetic Research   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE ACETYLTRANSFERASE PCAF; OLIGONUCLEOTIDE; PRAVASTATIN; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR GATA 3;

AGED; ARTICLE; CARDIAC PATIENT; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC VARIABILITY; HELA CELL; HOMOZYGOSITY; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MALE; MOUSE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROMOTER REGION; RESTENOSIS; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

AGE FACTORS; AGED; ANIMALS; CORONARY DISEASE; CORONARY RESTENOSIS; EPIGENESIS, GENETIC; EPIGENOMICS; FEMALE; HUMANS; MALE; MICE; P300-CBP TRANSCRIPTION FACTORS; POLYMORPHISM, GENETIC; RNA, MESSENGER; SEX FACTORS;

EID: 78651250895     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.199927     Document Type: Article

References (47)

1. Ross JS, Stagliano NE, Donovan MJ, et al. Atherosclerosis and cancer: common molecular pathways of disease development and progression. Ann NY Acad Sci 2001;947:271-92.
2. Agema WR, Jukema JW, Pimstone SN, et al. Genetic aspects of restenosis after percutaneous coronary interventions: towards more tailored therapy. Eur Heart J 2001;22:2058-74.
3. Monraats PS, Pires NM, Agema WR, et al. Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation 2005;112:2417-25.
4. Nordlie MA, Wold LE, Kloner RA. Genetic contributors toward increased risk for ischemic heart disease. J Mol Cell Cardiol 2005;39:667-79.
5. Gosden RG, Feinberg AP. Genetics and epigeneticsenature's pen-and-pencil set. N Engl J Med 2007;356:731-3.
6. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 2005;102:10604-9.
7. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005;352:1967-76.
8. Lill NL, Grossman SR, Ginsberg D, et al. Binding and modulation of p53 by p300/CBP coactivators. Nature 1997;387:823-7. (Pubitemid 27270910)
9. Pons D, de Vries FR, van den Elsen PJ, et al. Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease. Eur Heart J 2009;30:266-77.
10. Turunen MP, Aavik E, Yla-Herttuala S. Epigenetics and atherosclerosis. Biochim Biophys Acta 2009;1790:886-91.
11. Wei JQ, Shehadeh LA, Mitrani JM, et al. Quantitative control of adaptive cardiac hypertrophy by acetyltransferase p300. Circulation 2008;118:934-46.
12. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349-52.
13. Moodie FM, Marwick JA, Anderson CS, et al. Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-kappaB activation and proinflammatory cytokine release in alveolar epithelial cells. FASEB J 2004;18:1897-9.
14. Miao F, Gonzalo IG, Lanting L, et al. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem 2004;279:18091-7.
15. Vogel NL, Boeke M, Ashburner BP. Spermidine/spermine N1-acetyltransferase 2 SSAT2) functions as a coactivator for NF-kappaB and cooperates with CBP and P/CAF to enhance NF-kappaB-dependent transcription. Biochim Biophys Acta 2006;1759:470-7.
16. Liu L, Scolnick DM, Trievel RC, et al. P53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 1999;19:1202-9.
17. Di Stefano V, Soddu S, Sacchi A, et al. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage. Oncogene 2005;24:5431-42.
18. Okumura K, Mendoza M, Bachoo RM, et al. PCAF modulates PTEN activity. J Biol Chem 2006;281:26562-8.
19. Bucova M, Bernadic M, Buckingham T. C-reactive protein, cytokines and inflammation in cardiovascular diseases. Bratisl Lek Listy 2008;109:333-40.
20. Lowe GD. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost 2005;3:1618-27.
21. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009;27:2217-24.
22. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
23. Agema WR, Monraats PS, Zwinderman AH, et al. Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era. Eur Heart J 2004;25:1163-70.
24. Shepherd J, Blauw GJ, Murphy MB, et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol 1999;84:1192-7.
25. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
26. Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148-55.
27. Monraats PS, Pires NM, Schepers A, et al. Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB J 2005;19:1998-2004.
28. Heinemeyer T, Wingender E, Reuter I, et al. Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 1998;26:362-7.
29. Gobin SJ, Peijnenburg A, Keijsers V, et al. Site alpha is crucial for two routes of IFN gamma-induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA. Immunity 1997;6:601-11. (Pubitemid 27239351)
30. Ko LJ, Engel JD. DNA-binding specificities of the GATA transcription factor family. Mol Cell Biol 1993;13:4011-22.
31. Morris JF, Hromas R, Rauscher FJ III. Characterization of the DNA-binding properties of the myeloid zinc finger protein MZF1: two independent DNA-binding domains recognize two DNA consensus sequences with a common G-rich core. Mol Cell Biol 1994;14:1786-95.
32. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with imageJ. Biophoton Int 2004;11:36-42.
33. van den Maagdenberg AM, Hofker MH, Krimpenfort PJ, et al. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem 1993;268:10540-5.
34. Pires NM, Eefting D, de Vries MR, et al. Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. Heart 2007;93:922-7.
35. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
36. Mnjoyan ZH, Dutta R, Zhang D, et al. Paradoxical upregulation of tumor suppressor protein p53 in serum-stimulated vascular smooth muscle cells: a novel negativefeedback regulatory mechanism. Circulation 2003;108:464-71.
37. Kusama H, Kikuchi S, Tazawa S, et al. Tranilast inhibits the proliferation of human coronary smooth muscle cell through the activation of p21waf1. Atherosclerosis 1999;143:307-13.
38. Lee B, Kim CH, Moon SK. Honokiol causes the p21WAF1-mediated G(1)-phase arrest of the cell cycle through inducing p38 mitogen activated protein kinase in vascular smooth muscle cells. FEBS Lett 2006;580:5177-84.
39. Kato S, Ueda S, Yamaguchi M, et al. Overexpression of p21Waf1 induces apoptosis in immortalized human vascular smooth muscle cells. J Atheroscler Thromb 2003;10:239-45.
40. Patel VI, Daniel S, Longo CR, et al. A20, a modulator of smooth muscle cell proliferation and apoptosis, prevents and induces regression of neointimal hyperplasia. FASEB J 2006;20:1418-30.
41. Kiernan R, Bres V, Ng RW, et al. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 2003;278:2758-66.
42. Sarzi-Puttini P, Atzeni F, Doria A, et al. Tumor necrosis factor-alpha, biologic agents and cardiovascular risk. Lupus 2005;14:780-4.
43. Cipollone F, Prontera C, Pini B, et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 2001;104:921-7.
44. Wang K, Tarakji K, Zhou Z, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model. J Cardiovasc Pharmacol 2005;45:61-7.
45. Mocellin S, Rossi CR, Pilati P, et al. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 2005;16:35-53.
46. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-16.
47. Mayor S. Unravelling the secrets of ageing. BMJ 2009;338:a3024.